AUTL - Autolus Therapeutics plc
| Previous Close | 13.50 |
| Open | 12.95 |
| Bid | 12.79 x 1100 |
| Ask | 13.04 x 900 |
| Day's Range | 12.75 - 13.15 |
| 52 Week Range | 9.50 - 53.24 |
| Volume | 17,689 |
| Avg. Volume | 324,146 |
| Market Cap | 576.218M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.40 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 34.75 |
- Reuters
Czech billionaire Kellner's PPF Group expands in biotech with Autolus stake
Investment group PPF, controlled by the Czech Republic's richest man Petr Kellner, has acquired a 19.2% stake in biopharmaceutical firm Autolus Therapeutics , it said on Monday, making it the company's biggest shareholder. Autolus had a market capitalisation of $607 million at Friday's close, though its shares have lost 60% so far this year. PPF Group said that UK-based Autolus was developing a pipeline of next generation T-cell therapies - which use the body's immune system to target cancer cells - for both haematological cancers and solid tumours.
- GlobeNewswire
Autolus Announces Publication in Nature Medicine of Data Supporting the Development of AUTO1 for Treatment of Patients with ALL
Findings from Phase I CARPALL Trial Demonstrate that Autolus’ Novel CAR T Therapy, AUTO1, Induces Enhanced Anti-tumor Response Without Severe Cytokine Release Syndrome 86%.
- GlobeNewswire
Autolus Therapeutics to Participate in Upcoming Investor Conferences in September
Dr. Christian Itin, chairman and chief executive officer, will present at the Wells Fargo 2019 Healthcare Conference in Boston on Wednesday, September 4 at 3:00 p.m. ET and will host one-on-one meetings with attendees. A live webcast of the presentation will be available on the investor relations section of Autolus’ website at https://www.autolus.com. An archived replay will be available on the company’s website for a period of 90 days after the conference.
Motley FoolAutolus Therapeutics Plc (AUTL) Q2 2019 Earnings Call Transcript
AUTL earnings call for the period ending June 30, 2019.
- GlobeNewswire
Autolus Therapeutics Reports Second Quarter 2019 Financial Results and Operational Progress
LONDON, Aug. 08, 2019 -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today.
- GlobeNewswire
Autolus Therapeutics to Report Second Quarter 2019 Financial Results and Host Conference Call on August 8
LONDON, Aug. 02, 2019 -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today.
- Simply Wall St.
Did You Manage To Avoid Autolus Therapeutics's (NASDAQ:AUTL) 26% Share Price Drop?
It's easy to match the overall market return by buying an index fund. While individual stocks can be big winners...
- Zacks
Autolus Therapeutics (AUTL) in Focus: Stock Moves 8.5% Higher
Autolus Therapeutics (AUTL) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
- GlobeNewswire
Autolus Therapeutics to Participate in Upcoming Investor Conferences in June
LONDON, May 28, 2019 -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today.
- ACCESSWIRE
Autolus Therapeutics Plc to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 14, 2019 / Autolus Therapeutics Plc (NASDAQ: AUTL ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 14, 2019 at 8:30 AM ...
- GlobeNewswire
Autolus Therapeutics Reports First Quarter 2019 Financial Results and Operational Progress
LONDON, May 14, 2019 -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today.
- GlobeNewswire
Autolus Therapeutics to Report First Quarter 2019 Financial Results and Host Conference Call on May 14
LONDON, May 07, 2019 -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today.
- Insider Monkey
Is Autolus Therapeutics plc (AUTL) A Good Stock To Buy?
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]
- GlobeNewswire
Autolus Therapeutics Receives FDA Orphan Drug Designation for AUTO3 for Treatment of Acute Lymphoblastic Leukemia
Autolus Therapeutics plc (AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, announced that the United States Food and Drug Administration (FDA) has granted orphan drug designation to autologous enriched T-cells genetically modified with a retroviral vector to express two chimeric antigen receptors targeting CD19 and CD22 (AUTO3) for the treatment of acute lymphoblastic leukemia (ALL).
- GlobeNewswire
Autolus Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares
LONDON, April 15, 2019 -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today.
- Simply Wall St.
What Kind Of Shareholder Owns Most Autolus Therapeutics plc (NASDAQ:AUTL) Stock?
If you want to know who really controls Autolus Therapeutics plc (NASDAQ:AUTL), then you'll have to look at the makeup of its share registry. Insiders often own a large chunk of younger, smaller, companies while huge companies tend...
- Zacks
Autolus Therapeutics (AUTL) Catches Eye: Stock Jumps 5.6%
Autolus Therapeutics (AUTL) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
- GlobeNewswire
Autolus Announces Pricing of Public Offering
Autolus Therapeutics plc (AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the pricing of an underwritten public offering in the United States of 4,200,000 American Depositary Shares (“ADSs”) representing 4,200,000 ordinary shares at a public offering price of $24.00 per ADS, for total gross proceeds of approximately $100.8 million. All ADSs sold in the offering were offered by Autolus. In addition, Autolus has granted the underwriters a 30-day option to purchase up to an additional 630,000 ADSs at the public offering price, less underwriting discounts and commissions.
- GlobeNewswire
Autolus Announces Proposed Public Offering in the United States
Autolus Therapeutics plc (AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it intends to offer and sell 4,000,000 American Depositary Shares (“ADSs”) representing 4,000,000 ordinary shares in an underwritten public offering in the United States. Autolus also intends to grant the underwriters a 30-day option to purchase up to an additional 600,000 ADSs at the public offering price, less underwriting discounts and commissions. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed or the actual size or terms of the offering.
- PR Newswire
Arix Bioscience plc - Autolus Presents Initial AUTO1 Data at AACR
Arix Bioscience plc (ARIX.L) ("Arix"), a global venture capital company focused on investing in and building breakthrough biotech companies, notes that its portfolio company, Autolus Therapeutics plc (AUTL) ("Autolus"), has announced that Claire Roddie MB, PhD, FRCPath, honorary senior lecturer, Cancer Institute, University College London (UCL), presented today initial data from the ongoing Phase 1/2 ALLCAR19 trial of AUTO1 in adult acute lymphoblastic B cell leukemia (ALL) as a late-breaking poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2019 in Atlanta, Georgia. The announcement can be accessed on Autolus' investor website at https://www.autolus.com/investor-relations and full text of the announcement from Autolus is contained below.
- GlobeNewswire
Initial Results from Autolus Therapeutics’ ALLCAR19 Phase 1/2 Trial in Adult Acute Lymphoblastic Leukemia Presented at the AACR Annual Meeting
Autolus Therapeutics plc (AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, announced that Claire Roddie MB, PhD, FRCPath, honorary senior lecturer, Cancer Institute, University College London (UCL), presented today initial data from the ongoing Phase 1/2 ALLCAR19 trial of AUTO1 in adult acute lymphoblastic B cell leukemia (ALL) as a late-breaking poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2019 in Atlanta, Georgia. Relapsed / refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) in adults is an area of significant unmet clinical need.
- PR Newswire
Arix Bioscience plc - Autolus Announces Conference Call to Discuss AUTO1 ALLCAR19 Data Presentation at the AACR Annual Meeting 2019
LONDON , March 29, 2019 /PRNewswire/ -- Arix Bioscience plc (LSE: ARIX) ("Arix"), a global venture capital company focused on investing in and building breakthrough biotech companies, today notes ...
- GlobeNewswire
Autolus Therapeutics Announces Conference Call to Discuss AUTO1 ALLCAR19 Data Presentation at the AACR Annual Meeting 2019
LONDON, March 29, 2019 -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the.
- GlobeNewswire
Autolus Therapeutics Unveils Expanded Next Generation Technology and Pipeline and Provides Key Update on AUTO3 Program in Pediatric ALL at R&D Day
LONDON, March 26, 2019 -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next generation programmed T cell therapies for the.
- GlobeNewswire
Autolus Therapeutics to Host R&D Day on March 26, 2019
Company to highlight next-generation, novel programmed T cell therapies in development for hematological and solid tumor indications Program and webcast to begin at 8:00 am ET.
